Grant: CIHR Fellowship
Direct Payment
$150,000.00
Prediction of antidepressant response using combined neuroimaging and pharmacogenetics
EF 2013-14
Résumé
Major depressive disorder (MDD), affecting an estimated 350 million people worldwide, poses a serious social and economic threat. Antidepressants are standard treatment for MDD. However, not all patients respond adequately to medication, leading to increased burden of the disease, higher treatment costs and "trial-and-error" treatment. Currently, there are no valid clinical prediction factors for an individual's treatment response available yet, and one of the major research challenges remains to identify biological markers predicting response.
There is growing evidence that genetic factors have a high impact on antidepressant response as demonstrated by a number of candidate gene and genome-wide studies in the past decade. In addition, several neuroimaging correlates of antidepressant response have been identified. This project aims to link genetic factors and their neuroimaging correlates of response using state-of-the-art methods. In a large and well-characterized sample, we will investigate how genetic factors known to be associated with treatment response impact on brain morphology and connectivity using structural and functional magnetic resonance imaging. Based on these findings, we will create an algorithm integrating genetics and neuroimaging information to predict treatment response. This algorithm and its impact on treatment outcome will then be tested prospectively in patients with MDD.
To our knowledge, this is the first such study of its kind, and the results of this study will be highly innovative. Our study will provide novel insight on how genetic factors and brain networks influencing treatment response interact. Moreover, incorporation of both genetic and neuroimaging information to predict treatment response will lead to a more powerful strategy for personalized therapy than either tool alone. Therefore, this identification of response biomarkers will significantly help to improve future treatment outcomes for patients with MDD.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Germany
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
300970
Name
Lett Tristram A
Country
Germany
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Prediction of antidepressant response using combined neuroimaging and pharmacogenetics
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Depression; Genetics; Mental Health; Neuroimaging; Neuroscience; Pharmacogenetics
Abstract
Major depressive disorder (MDD), affecting an estimated 350 million people worldwide, poses a serious social and economic threat. Antidepressants are standard treatment for MDD. However, not all patients respond adequately to medication, leading to increased burden of the disease, higher treatment costs and "trial-and-error" treatment. Currently, there are no valid clinical prediction factors for an individual's treatment response available yet, and one of the major research challenges remains to identify biological markers predicting response.
There is growing evidence that genetic factors have a high impact on antidepressant response as demonstrated by a number of candidate gene and genome-wide studies in the past decade. In addition, several neuroimaging correlates of antidepressant response have been identified. This project aims to link genetic factors and their neuroimaging correlates of response using state-of-the-art methods. In a large and well-characterized sample, we will investigate how genetic factors known to be associated with treatment response impact on brain morphology and connectivity using structural and functional magnetic resonance imaging. Based on these findings, we will create an algorithm integrating genetics and neuroimaging information to predict treatment response. This algorithm and its impact on treatment outcome will then be tested prospectively in patients with MDD.
To our knowledge, this is the first such study of its kind, and the results of this study will be highly innovative. Our study will provide novel insight on how genetic factors and brain networks influencing treatment response interact. Moreover, incorporation of both genetic and neuroimaging information to predict treatment response will lead to a more powerful strategy for personalized therapy than either tool alone. Therefore, this identification of response biomarkers will significantly help to improve future treatment outcomes for patients with MDD.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lett, Tristram A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~